Objective To probe a satisfactory surgical management of the limbsalvage for osteogenic malignant tumors around the knees. Methods From January1989 to December 2001, 42 patients (19 males and 18 females, aged 12-46) with osteogenic malignant tumors around the knees underwent surgical management of the limb salvage, including prosthesis replacement, allogenous bone grafting, and bone cement with adriamycin filled. Based on the pathological examination, osteosarcoma was found in 11 patients, synoviosarcoma in 4 patients, malignant fibrous histiocytoma in 3 patients, and giant cell tumor of the bone in 19 patients. All the patients underwent neoadjuvant chemotherapy for 1-2 courses before operatioexcept the patients with giant cell tumor of the bone. The patients underwent prosthesis replacement, allogenous bone grafting, bone cement with adriamycin filled, and postoperative chemotherapy. By the Enneking evaluating system, the patients were assessed on their reconstructed limb functions after the reconstructive operation for the musculoskeleta malignant tumors. Of the patients, 37 were followed up after operation. Results According to the follow-up for 3-11 years (mean, 5.6 years) in the 37 patients, 2 patients had recurrence and metastasis of the tumor, and died 3 and 4 years after operation, respectively. One patient underwent amputation of the limb for local recurrence of the tumor. One patient had amputation of the limb for the preoperative radiotherapy and the infection and necrosis of the operative wound after the limb-salvage surgery. Two patients had amputation of the limb for the rejection of the allogenous bone graft and theformation of the fistula.Thirty-one patients had good wound healing andgood functions of the limb. The results were evaluated by the Enneking evaluating system as follows: excellent in 7 patients, good in 14, fair in 10, and poor in 6. Conclusion Making an early diagnosis, recognizing the operative indication, choosing the operative method, and performing the preoperative and postoperative chemotherapy and/or radiotherapy are the keys to achieving an ideal limb-salvage surgery for osteogenic malignant tumors around the knees.
Objective To evaluate the diagnostic value of antikeratin antibody (AKA) for rheumatoid arthritis (RA). Methods Systematic and comprehensive literature was searched in PubMed (1966 to June 2010), The Cochrane Library (Issue 6, 2010), CBM (1978 to June 2010), CNKI (1994 to June 2010), VIP (1989 to June 2010), and CMA Digital Periodicals (1997 to June 2010). The diagnosis studies of antikeratin antibody for rheumatoid arthritis were included. The quality assessment of diagnostic accuracy studies (QUADAS) items were used to assess the quality of the included studies. The Meta-Disc (version 1.4) software was used to analyze the data. Results A total of 69 trials involving 14 890 participants were included. The results of meta-analyses showed that compared with the RA classification criteria revised by American Rheumatism Association (ARA), the summary sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, OR value, and summary receiver operating characteristic curve of antikeratin antibody were 0.41 (0.39, 0.42), 0.94 (0.94, 0.95), 9.52 (7.21, 12.57), 0.63 (0.60, 0.66), 15.24 (11.62, 19.98), and 0.613 6, respectively. Conclusion Antikeratin antibody might be one of the most effective diagnoses for rheumatoid arthritis. The clinicians should combine other autoantibodies with AKA to diagnose rheumatoid arthritis.